This website uses cookies. By using this website, you agree to our Cookie Policy.
January 03, 2021
Cadwalader Intellectual Property Group chair and partner Dorothy Auth shares her insights on why generic drug settlement legislation will be among the patent policy issues to watch in 2021.
